Cognitive Behavioral Therapy Plus Drug Treatment for Obsessive Compulsive Disorder

Obsessive-Compulsive Disorder Clinical Trial

— Aug1  

Official title:

CBT Augmentation for SRI Pharmacotherapy in OCD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00045903
• Other study ID #: IRB #4734R
• Secondary ID: R01MH045436-01DS
• Status: Completed
• Phase: N/A
• First received: September 13, 2002
• Last updated: April 22, 2014
• Start date: August 2000
• Est. completion date: January 2007

Study information

• Verified date: October 2012
• Source: New York State Psychiatric Institute
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the effectiveness of two cognitive behavioral therapies (CBTs) in treating obsessive compulsive disorder (OCD) in patients who are taking medication but still have residual symptoms.

Description:

Participants remain on their current OCD medication and are randomly assigned to receive one of two CBTs: exposure and ritual prevention or stress management therapy. Exposure and ritual prevention involves imaginal and in-vivo exposure and requires that participants refrain from ritualizing. Stress management involves relaxation, assertiveness training, and structured problem-solving. Therapy occurs twice per week for 2 months. Participants are assessed verbally by an independent evaluator and are asked to complete self-rating forms. Patients who respond are followed for up to 1 additional year. Participants continue to take the same medication and the same monthly therapy for the first 6 months of follow-up. During the second 6 months of follow-up, participants discontinue therapy but continue taking the same medication.

For information on a related study, please follow this link:

http://clinicaltrials.gov/show/NCT00389493

Recruitment information / eligibility

• Status: Completed
• Enrollment: 136
• Est. completion date: January 2007
• Est. primary completion date: January 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Obsessive-Compulsive Disorder (OCD) diagnosis

• Currently taking a serotonin reuptake inhibitor (SRI, i.e. clomipramine, fluoxetine, fluvoxamine, paroxetine, sertraline, or citalopram) for OCD

Exclusion Criteria:

• Medical or psychiatric conditions that would make participation in the study hazardous

• Intensive cognitive-behavioral therapy while on an adequate dose and duration of an SRI for OCD

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Compulsive Behavior
• Obsessive-Compulsive Disorder

Intervention

Behavioral:
• Exposure and Ritual Prevention (Cognitive Behavioral Therapy)

• Stress Management Therapy (Cognitive Behavior Therapy)

Locations

Country	Name	City	State
United States	New York State Psychiactic Institute, Anxiety Disorders Clinic	New York	New York
United States	University of Pennsylvania Center for the Treatment and Study of Anxiety	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
New York State Psychiatric Institute	National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Obsessive-compulsive symptoms measured at Month 2		2 months	No
Secondary	General functioning measured at Month 2		2 months	No